What happened
SpyGlass Pharma, Inc. (NASDAQ: SGP) said it closed its purchase of Advanced Vision Science, Inc. on October 1, 2026. SpyGlass said it acquired 100% of AVS, an ophthalmic medical device company that makes intraocular lenses and lens materials.
The purchase price was based on $13 million, subject to customary adjustments. Before the closing, AVS supplied intraocular lenses to SpyGlass. The press release said AVS is the current supplier of SpyGlass's IOL in its two Phase 3 registrational trials of the BIM-IOL System. It also said the acquisition secures scalable commercial IOL manufacturing capacity and speeds the path to premium lens options.
Key numbers
| Metric | Latest | Change | Source |
|---|---|---|---|
| Purchase price at closing | $13 million | SEC 8-K | |
| AVS equity acquired | 100% | SEC 8-K | |
| Current Phase 3 registrational trials supplied | 2 Phase 3 registrational trials | Press release | |
| Bimatoprost delivery duration | 3 years | Press release |
Why it matters
OptimistFi's case is that long-acting ophthalmic delivery of approved medicines can create per-share value if trial execution and cash use stay on track. This deal supports that view by bringing a key IOL supply link in-house and leaving the current Phase 3 supply chain in place.
SpyGlass says the BIM-IOL System is made to be implanted during routine cataract surgery. It is designed to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It is also designed to deliver three years of bimatoprost, a medicine approved for topical use by the U.S. Food and Drug Administration in 2001.
The shift is simple. SpyGlass moved from outsourcing a key IOL input to owning AVS. That gives it direct control over part of the supply chain the program depends on.
The filing also gives the limits. SpyGlass says the expected benefits depend on its ability to manufacture IOLs, avoid production delays and control costs. The $13 million figure is not final because the purchase price is still subject to a customary post-closing adjustment.
Browse: stock research on every company OptimistFi covers
What's next
The next quarterly report is the next scheduled check on integration, cash use and supply execution. A report that shows a smooth AVS handoff and on-schedule manufacturing would strengthen the case. A report that shows delays or higher costs would weaken it. The final cash cost is still open because the purchase price remains subject to a customary post-closing adjustment.
More from OptimistFi
- SGP stock: the SpyGlass Pharma thesis, its status and the next test to watch
- Autonomix Medical, Inc. (NASDAQ: AMIX) Gets a Clearer FDA Path
- FactSet Research Systems Inc. (NYSE: FDS) Guides to Slower ASV Growth
- Broadcom Inc. (NASDAQ: AVGO) Adds AI Substrate Capacity
- Stock research on every company OptimistFi covers
- Latest stock research and investment-case updates
- OptimistFi: evidence-first equity research
Sources
- SEC 8-K — Closing of the AVS acquisition and purchase price at October 1, 2026.
- Press release — AVS acquisition, supplier role in Phase 3 trials and manufacturing capacity.
Read the full OptimistFi thesis on SpyGlass Pharma, Inc.: https://optimistfi.com/stocks/SGP
See what would break the SpyGlass Pharma, Inc. thesis and track it live on the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
The full SpyGlass Pharma, Inc. investment case, its status and the next test to watch live on the SpyGlass Pharma, Inc. thesis page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.
-logo-1200x675.png){kind=logo}
